Lack of Association Between Low Density Lipoprotein Particle Size and On-Treatment Platelet Reactivity in Patients With Coronary Artery Disease.
10.4070/kcj.2012.42.8.551
- Author:
Do Yoon KANG
1
;
Han Mo YANG
;
Kyung Woo PARK
;
So Ryoung LEE
;
Min Ho LEE
;
Dong Won LEE
;
Hae Young LEE
;
Hyun Jae KANG
;
Bon Kwon KOO
;
In Ho CHAE
;
Dong Ju CHOI
;
Hyo Soo KIM
;
Cheol Ho KIM
Author Information
1. Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea. hanname@medimail.co.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Lipoproteins;
Low-density lipoprotein;
Platelet Function Tests
- MeSH:
Aspirin;
Blood Platelets;
Coronary Artery Disease;
Coronary Vessels;
Electrophoresis;
Humans;
Lipoproteins;
Lipoproteins, LDL;
Male;
Particle Size;
Percutaneous Coronary Intervention;
Platelet Function Tests;
Risk Factors;
Ticlopidine
- From:Korean Circulation Journal
2012;42(8):551-557
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Small dense low density lipoproteins (sd-LDL) are a risk factor for coronary artery disease and are known to stimulate platelet function in vitro. This study aimed to evaluate whether high proportion of sd-LDL is associated with high on-treatment platelet reactivity (HOPR). SUBJECTS AND METHODS: From January 2009 to March 2010, 439 subjects (mean age: 64.3+/-9.7, Male : Female=306 : 133) were enrolled from the low density LIPOProtein-cholesterol Size measurement Registry with coronary artery disease, who had undergone elective percutaneous coronary intervention and measured both LDL particle size and on-treatment platelet reactivity (OPR). Mean LDL particle size was measured by gradient gel electrophoresis (Quantimetrix, Lipoprint(TM)) and OPR by the VerifyNow(TM) system (aspirin and P2Y12). RESULTS: Between pattern A (large, buoyant LDL dominant) and B (sd-LDL dominant) population, there were no significant difference in OPR to aspirin (441.3+/-71.9 vs. 434.07+/-63.45 aspirin reaction units, p=0.351) or clopidogrel (237.9+/-87.3 vs. 244.9+/-80.7 P2Y12 reaction units, p=0.465). There was no difference in LDL particle size between patients with HOPR compared with non-HOPR patients (aspirin: 26.8+/-0.5 vs. 26.7+/-0.6 nm, p=0.078, clopidogrel: 26.7+/-0.6 vs. 26.8+/-0.5 nm, p=0.857). Pearson's correlation coefficients between LDL particle size and platelet reactivity were not statistically significant (aspirin assay: r=0.080, p=0.098, P2Y12 assay: r=-0.027, p=0.568). CONCLUSION: There was no significant association between LDL particle size and OPR in patients with coronary artery disease.
